Group items tagged

The objective of this FOA is to advance non-sputum-based tuberculosis (TB) diagnostics for use in HIV-1 infected and HIV-1 exposed uninfected children (HEU) for improved, simplified, rapid and decentralized diagnosis of TB disease. This opportunity will support discovery and validation of novel biomarkers useful for TB diagnosis or the development/optimization and early validation of novel TB diagnostic technologies.

DHAPP's goal is to maximize program impact by focusing on the drivers of the HIV epidemic specific to the military and to support the development of interventions and programs that address these issues. DHAPP works with militaries of foreign countries to devise plans

The aim of the CDA is to support the next generation of researchers and to significantly improve outcomes and quality of life for breast cancer patients. The award will provide up to $100,000 per year for two years to be combined with matching funds or in kind contribution from the applicant's institution. Neither ASTRO nor BCRF will pay indirect costs as part of this award. One award will be funded. Research must be focused on understanding or treatment of breast cancer and include use or impact of radiation treatment.

The aim of the CDA is to support the next generation of researchers and to significantly improve outcomes and quality of life for prostate cancer patients. The award will provide up to $75,000 per year for three years to be combined with matching funds or in kind contribution from the applicant's institution. Neither ASTRO nor PCF will pay indirect costs as part of this award. One award will be funded. Research must be focused on understanding or treatment of prostate cancer and include use or impact of radiation treatment.

This Funding Opportunity Announcement (FOA) encourages formative research, intervention development, and pilot-testing of interventions. Primary scientific areas of focus include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention, treatment or services research. For the purposes of this FOA, "intervention" may include behavioral, social, or structural approaches, as well as combination biomedical and behavioral approaches that prevent the acquisition and transmission of HIV infection, or improve clinical outcomes for persons who are HIV infected.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and optimize delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) Recommendation E: "To realize the potential of cancer prevention and early detection in our nation, NCI should sponsor an initiative to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development. This initiative should include demonstration projects that will show how cancer screening programs can simultaneously save lives, improve quality of life, and reduce healthcare costs."

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and optimize delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) Recommendation E: "To realize the potential of cancer prevention and early detection in our nation, NCI should sponsor an initiative to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development. This initiative should include demonstration projects that will show how cancer screening programs can simultaneously save lives, improve quality of life, and reduce healthcare costs."

The key element of the national HIV/AIDS program is ART scale up contributing towards strategic goals of treatment cascade. This project will build on the successful creation of a HIV medical information system through the ACCESS project by scaling up implementation of the MIS to treatment sites in all 12 PEPFAR focus oblasts, including capacity building of healthcare workers, improving information management, analysis and use. The project will also develop and implement a laboratory information system module. In addition, the project will work with the treatment sites to implement quality improvement and facility index testing activities in coordination with other PEPFAR and Global Fund supported activities. The major expected project results are 1) functional HIV MIS is operated by a GOU affiliated Operator at treatment sites in the 12 PEPFAR priority regions and Vinnitsa; 2) MIS data used by sites, GoU, PEPFAR , and other stakeholders; 3) laboratory module implemented; 3) quality improvement activities are implemented at all supported treatment sites; 4) high coverage facility index testing is performed at supported sites.

This Funding Opportunity Announcement (FOA) encourages applications that develop and test multilevel interventions to improve follow-up to abnormal screening tests for breast, cervical, colorectal, or lung cancers. Improving follow-up to abnormal screening tests is dependent on factors at the patient, provider, clinical team, clinic, healthcare institution, or community setting levels. Appropriate applications for this FOA should propose to intervene at two or more levels, and measure outcomes at three or more levels, while accounting for interactions that occur between and across levels.

The objective of this award is to provide additional career development support for outstanding Respiratory Therapists (RTs) who conduct research (clinical or translational), including detection, inhalation therapies, clinical care, diagnostics, and therapeutic tools in alpha-1 antitrypsin deficiency (AATD)-related lung disease.